Search results
Results from the WOW.Com Content Network
Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This new coverage could also make it easier once CRISPR ...
CRSP Market Cap data by YCharts. 3. Intensive competition. The success of CRISPR Therapeutics will depend on its ability to bring multiple new drugs to the market to support a more viable business ...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...
CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. But don't expect CRISPR to try to offload ...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $83.39, marking a +1.81% move from the previous day. Skip to main content. 24/7 Help. For premium support please call: 800 ...
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $64.40, moving +1.31% from the previous trading session. CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should ...
CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day.
CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.